Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PAVmed ( (PAVM) ) has shared an announcement.
On January 21, 2026, PAVmed Inc. announced it had regained compliance with the Nasdaq Capital Market’s $1 minimum bid price requirement for continued listing, following a period beginning January 23, 2025, when its stock had traded below the $1 threshold for at least 30 consecutive business days. Nasdaq determined that between January 2 and January 19, 2026, PAVmed’s closing bid price had been at or above $1 per share, restoring the company’s compliance with listing rules and reducing the immediate risk of delisting, a development that stabilizes its market position and offers greater reassurance to investors and other stakeholders.
The most recent analyst rating on (PAVM) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
The score is held down primarily by weak financial fundamentals, including persistent losses and negative operating/free cash flow. Technicals provide some near-term support with the stock trading above key shorter-term moving averages, while the earnings call adds moderate positives around Medicare progress and improved runway, but ongoing restructuring and stagnant revenue growth keep risk elevated.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. operates in the medical technology sector, developing and commercializing innovative medical devices and healthcare solutions aimed at improving patient care and clinical outcomes in targeted healthcare markets.
Average Trading Volume: 950,133
Technical Sentiment Signal: Sell
Current Market Cap: $6.58M
Find detailed analytics on PAVM stock on TipRanks’ Stock Analysis page.